Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 2.104736125
Author: Trendlyne DVM scores

Risky Value

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

15.84 -0.19 (-1.19%)

117.58% Gain from 52W Low

948.1K

XNAS Volume

XNAS 14 May, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Aurinia Pharma Inc is on 15 May 2026 for the purpose of Aurinia Pharmaceuticals Inc Annual General Meeting for 2026 See details

Low Financial Strength

27.8 / 100

Affordable Valuation

54.8 / 100

Technically Neutral

58.0 / 100

Risky Value These stocks have weak financials and average momentum. They may be affordable, but investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 7%

7 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

117.58% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart